Histogen: Rises on COVID-19 treatment development deal with Amerimmune

Histogen

27/10/2020 12:43

** Regenerative medicine maker's shares  HSTO.O  rise 6.6%
to $2.09 premarket
    ** Co enters into development and commercialization
agreement with Amerimmune LLC for experimental COVID-19
treatment  urn:newsml:reuters.com:*:nGNX44CpSw
    ** HSTO has received U.S. FDA nod to start early-stage trial
for the experimental treatment, emricasan, in mild COVID-19
patients
    ** Amerimmune to lead development of emricasan, HSTO to
retain ownership; has chosen 2 sites in New York City to conduct
the study
    ** Co expects to start trial by end of 2020
    ** Amerimmune can sell emricasan under certain conditions to
support future third-party partnering transactions; cos to share
profit equally if such partnership occurs
    ** HSTO down 51% YTD as of Monday's close

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))